Business Wire

THALES

4.6.2024 09:01:35 CEST | Business Wire | Press release

Share
The DVLA and Thales Cut Carbon Footprint of UK Driving Licence and Residence Cards

The United Kingdom government’s Driver and Vehicle Licensing Agency (DVLA) partners with Thales to reduce the carbon footprint of its driving licences as well as tachograph and residence cards. Since 2018, Thales has cut by over one third the CO2 emissions associated with the 12 million cards it supplies to the DVLA every year, without compromising the outstanding security, durability and value-for-money provided by these products.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240604196678/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(credit: Shutterstock – Jubemo/Thales)

The DVLA is responsible for maintaining accurate records of more than 52 million drivers in Great Britain and more than 46 million vehicles across the UK. It is also recognised as a centre of excellence for sourcing and issuing secure national documents. Since 2012, Thales has supplied the DVLA with polycarbonate driving licences, a range of tachograph cards (for operations such as recording and storing the activity of commercial drivers), and residence cards for EU citizens to prove their right to live and work in the UK.

Key initiatives undertaken by Thales include adoption of eco-design principles throughout its identity card portfolio. For example, the size of the contactless microcontrollers embedded in the UK’s tachograph and residence cards has been halved, resulting in an equivalent reduction in CO2 microcontroller emissions while maintaining applications and security features unchanged.

In addition, Thales’ factories manufacturing the cards are accredited to the ISO 50001 standard, which focuses on energy efficiency. All these factories use 100% renewably electricity, accounting for over 70% of their total energy consumption. These improvements resulted in a reduction of over 80% of manufacturing related emissions (scope 1 and 2) since 2018.

For the remaining emissions of DVLA cards and on a yearly basis, Thales invests in high quality carbon offsetting programs with independently recognized carbon compensation organization such as Climate Impact Partners. For the DVLA contract, these include planting forests in the UK, restoring mangroves in Kenya, and distributing clean energy stoves in Bangladesh. In total, Thales has now offset 3,000 tonnes of CO2 emissions on behalf of the DVLA.

“Just like the DVLA, Thales is on the road to net zero and uses industry standard tools to calculate the Life Cycle Assessments of its products. This comprehensive calculator1 assesses the environmental impact of materials, packaging, transportation, document production and distribution, as well as end of life. Together with DVLA we are continually exploring new opportunities to improve the sustainability of the millions of cards supplied by Thales, looking for more responsible materials and solutions. At the same time, we remain focused on the need to maintain the security and integrity of identity credentials and deliver exceptional value for money for governments and public bodies” said Nathalie Gosset, Vice President Identity Document Solutions at Thales

1 This approach was developed with Quantis, a leading environmental sustainability consultancy, and is now supported by Solinnen, an expert consultancy specialising in Life Cycle Assessment, following recognised standards which consider the full life cycle of the products assessed and covers associated scope 1, 2 and 3.

About Thales

Thales (Euronext Paris: HO) is a global leader in advanced technologies specialized in three business domains: Defence & Security, Aeronautics & Space, and Cybersecurity & Digital identity.

It develops products and solutions that help make the world safer, greener and more inclusive.

The Group invests close to €4 billion a year in Research & Development, particularly in key innovation areas such as AI, cybersecurity, quantum technologies, cloud technologies and 6G.

Thales has close to 81,000 employees in 68 countries. In 2023, the Group generated sales of €18.4 billion.

PLEASE VISIT

Thales Group
Digital Identity & Security

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240604196678/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sofinnova Partners Closes Oversubscribed €82 Million Sofinnova MD Start IV Fund to Create the Next Generation of Medtech Companies28.9.2026 08:00:00 CEST | Press release

The new fund extends Sofinnova’s 20-year track record of company creation with capacity to launch six to eight new ventures across Europe and the US Sofinnova Partners ("Sofinnova"), a leading European life sciences venture capital firm based in Paris, London, and Milan, today announced the final close of Sofinnova MD Start IV at €82 million. The fund, which was oversubscribed, will help expand Sofinnova's medtech company-creation strategy across Europe and the US with greater capacity to launch new ventures and support them through key stages of development. With plans to launch six to eight new medtech companies over the next five years, Sofinnova MD Start IV will support ventures from inception through key clinical and operational milestones, providing founders with both capital and hands-on support. Sofinnova MD Start's approach combines clinical insight, entrepreneurial talent, and operational expertise to tackle significant unmet medical needs. The previous fund, Sofinnova MD Sta

Ant International’s Antom Upgrades Southeast Asia Leadership Structure to Drive Regional Synergy in the AI Era28.9.2026 07:18:00 CEST | Press release

Antom, a leading merchant payment and digitisation services provider under Ant International, today announced a series of key appointments for its operations in Southeast Asia to further strengthen the synergy among its regional brands and better serve regional merchants with streamlined full-stack AI-native solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260927431282/en/ Nabilah Alsagoff, co-founder and former chief operating officer of DOKU, Indonesia's leading payment fintech company, has been appointed as Head of Product, Antom SEA. In her new role, the payment veteran will oversee product development and innovation and drive a unified product roadmap for the overall SEA region. Chris Yeo, former chief executive officer (CEO) of DOKU, will take on the role as Head of Antom Philippines, and Country Head of 2C2P Philippines. With his long experience at DOKU, Grab and PayPal, Chris will also oversee the execution

UAE Opens 15th UN Congress on Crime Prevention and Criminal Justice and Launches Pledge4Justice with First Pledge of Up to USD 5 Million26.9.2026 22:51:00 CEST | Press release

The 15th United Nations Congress on Crime Prevention and Criminal Justice – Abu Dhabi 2026 kicked off today at ADNEC Centre Abu Dhabi. Set to run until 1 October, the Congress attracts representatives from over 97 countries, including over 32 ministers of justice and interior ministers, alongside senior officials, judges, prosecutors, experts, and youth from around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260926005703/en/ UAE Opens 15th UN Congress on Crime Prevention and Criminal Justice and Launches Pledge4Justice with First Pledge of Up to USD 5 Million (Photo: AETOSWire) The opening session witnessed the adoption of the Abu Dhabi Declaration, which serves as the Congress's principal political and strategic outcome document and will guide international priorities and cooperation in crime prevention, criminal justice and the rule of law over the next five years. The Declaration is structured around four pi

Future Health Convenes Global Health Leaders at UNGA to Advance Health System Transformation at Scale26.9.2026 17:21:00 CEST | Press release

High-level dialogue explored how predictive and preventive health systems can deliver better health outcomes worldwide. Ministers, senior government representatives, and health leaders from 15 countries shared approaches to building health systems that predict risk, prevent disease, and support earlier intervention at population scale. Participants identified population-level data, financing, and delivery capacity as essential to turning earlier insight into action. Trust, community reach, and inclusive design were recognised as critical to ensuring that earlier insight and intervention are delivered effectively and equitably Future Health – A Global Initiative by Abu Dhabi convened Ministers, senior government representatives, and global health leaders in New York on the sidelines of the 81st Session of the United Nations General Assembly (UNGA 81). The high-level dialogue set out practical priorities for moving health systems from reactive treatment towards prediction, prevention, an

Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva26.9.2026 01:00:00 CEST | Press release

-Once-daily oral ALK2 inhibitor approved to reduce the volume of total new heterotopic ossification in patients aged 12 years and older with FOP-Atebrioz expected to be available in the United States in October through Mirum Access Plus (MAP), with eligible patients paying as little as $0 per month-PROGRESS pediatric development program continues to evaluate zilurgisertib in children aged 2 to <12 years Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Atebrioz™ (zilurgisertib) tablets to reduce the volume of total new heterotopic ossification (HO) in adult and pediatric patients aged 12 years and older with fibrodysplasia ossificans progressiva (FOP). The recommended dose of Atebrioz is 100 mg administered orally, once daily. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260925436454/en/ “Today marks an important milestone for pe

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye